arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
By Dong Xu, Zhangfan Yang, Junchuang Cai, Sisi Yuan, Zexuan Zhu, Jianqiang Li, Junkai Ji
arXiv:2607. 01105v1 Announce Type: new Abstract: We present SynLaD, a latent diffusion framework for small-molecule generation that unifies ligand-based drug design objectives (what to make) with synthetic accessibility (how to make it).
By Miruna Cretu, John Bradshaw, Patricia Suriana, Saeed Saremi, Omar Mahmood, Kirill Shmilovich, Kangway Chuang, Vishnu Sresht, Colin Grambow
arXiv:2505. 08774v2 Announce Type: replace-cross Abstract: Designing molecules that are both property-optimal and readily synthesizable is a central challenge in drug discovery.
By Jeff Guo, V\'ictor Sabanza-Gil, Olha Semenenko, Oleksii Hrabovskyi, Mykola Protopopov, Anna Kapeliukha, Oleksandr Mosia, Sofiia Hatych, Diana Alieksieieva, Tom Nelis, Patrick Molliet, Helena Sol\'e-\`Avila, Valentas Olikauskas, Nina Aregger, Irina Morozova, Joseph Schmidt, Zlatko Jon\v{c}ev, Olga Tarkhanova, Petro Borysko, Jerome Waser, Bruno Correia, Jeremy Luterbacher, Philippe Schwaller
arXiv:2608. 17567v1 Announce Type: cross Abstract: Pretrained molecular language models are increasingly used as molecular encoders for learning structure-property relationships.
By Henrik Wille, Luis-Finley Sch\"utz, Felix Strieth-Kalthoff
arXiv:2607. 18144v1 Announce Type: cross Abstract: Structure-based drug design (SBDD) leverages the 3D structure of protein targets, often complemented by other spatial constraints, to generate candidate binding molecules.
By Thomas MacDougall, Maksim Kuznetsov, Roman Schutski, Rim Shayakhmetov, Maxim Malkov, Vladimir Aladinskiy, Alex Aliper, Alex Zhavoronkov
arXiv:2607. 19237v1 Announce Type: new Abstract: Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics.
By Yiming Qin, Kai Yi, Miruna Cretu, Sjors H. W. Scheres, Pietro Li\`o, Pascal Frossard